BACKGROUND: Chronic granulomatous disease (CGD) is a genetic disorder of the phagocyte NADPH oxidase, which predisposes patients to infections and inflammatory complications, including severe colitis. Management of CGD colitis is a challenge because standard immunosuppressive therapy increases the risk of infection in already immunocompromised hosts. METHODS: We report the use of infliximab in 5 patients with CGD. RESULTS: Infliximab administration predisposed patients to severe infections with typical CGD pathogens but not mycobacteria, as reported with infliximab in other conditions. In addition to infections, infliximab administration led to successful closure of fistulae, sometimes with other untoward consequences. Infliximab-associated complications were associated with 2 deaths. CONCLUSIONS: Infliximab use in the treatment of CGD inflammatory bowel disease requires aggressive antimicrobial prophylaxis, assiduous surveillance for infection, and vigilance for untoward gastrointestinal complications. This experience suggests that infliximab therapy is effective but has untoward consequences in patients with CGD.
BACKGROUND:Chronic granulomatous disease (CGD) is a genetic disorder of the phagocyte NADPH oxidase, which predisposes patients to infections and inflammatory complications, including severe colitis. Management of CGD colitis is a challenge because standard immunosuppressive therapy increases the risk of infection in already immunocompromised hosts. METHODS: We report the use of infliximab in 5 patients with CGD. RESULTS:Infliximab administration predisposed patients to severe infections with typical CGD pathogens but not mycobacteria, as reported with infliximab in other conditions. In addition to infections, infliximab administration led to successful closure of fistulae, sometimes with other untoward consequences. Infliximab-associated complications were associated with 2 deaths. CONCLUSIONS:Infliximab use in the treatment of CGDinflammatory bowel disease requires aggressive antimicrobial prophylaxis, assiduous surveillance for infection, and vigilance for untoward gastrointestinal complications. This experience suggests that infliximab therapy is effective but has untoward consequences in patients with CGD.
Authors: J M van der Klooster; R J Bosman; H M Oudemans-van Straaten; J I van der Spoel; J P J Wester; D F Zandstra Journal: Intensive Care Med Date: 2003-11-05 Impact factor: 17.440
Authors: Brahm H Segal; Wei Han; Jennifer J Bushey; Myungsoo Joo; Zahida Bhatti; Joy Feminella; Carly G Dennis; R Robert Vethanayagam; Fiona E Yull; Maegan Capitano; Paul K Wallace; Hans Minderman; John W Christman; Michael B Sporn; Jefferson Chan; Donald C Vinh; Steven M Holland; Luigina R Romani; Sarah L Gaffen; Michael L Freeman; Timothy S Blackwell Journal: PLoS One Date: 2010-03-16 Impact factor: 3.240
Authors: Elizabeth M Kang; Betty E Marciano; SukSee DeRavin; Kol A Zarember; Steven M Holland; Harry L Malech Journal: J Allergy Clin Immunol Date: 2011-04-17 Impact factor: 10.793
Authors: Meghna Alimchandani; Jin-Ping Lai; Phyu Phyu Aung; Sajneet Khangura; Natasha Kamal; John I Gallin; Steven M Holland; Harry L Malech; Theo Heller; Markku Miettinen; Martha M Quezado Journal: Am J Surg Pathol Date: 2013-09 Impact factor: 6.394
Authors: Katherine J Hahn; Nancy Ho; Lynne Yockey; Samantha Kreuzberg; Janine Daub; Amy Rump; Beatriz E Marciano; Martha Quezado; Harry L Malech; Steven M Holland; Theo Heller; Christa S Zerbe Journal: Am J Gastroenterol Date: 2015-06 Impact factor: 10.864
Authors: Rebecca A Marsh; Jennifer W Leiding; Brent R Logan; Linda M Griffith; Danielle E Arnold; Elie Haddad; E Liana Falcone; Ziyan Yin; Kadam Patel; Erin Arbuckle; Jack J Bleesing; Kathleen E Sullivan; Jennifer Heimall; Lauri M Burroughs; Suzanne Skoda-Smith; Shanmuganathan Chandrakasan; Lolie C Yu; Benjamin R Oshrine; Geoffrey D E Cuvelier; Monica S Thakar; Karin Chen; Pierre Teira; Shalini Shenoy; Rachel Phelan; Lisa R Forbes; Deepak Chellapandian; Blachy J Dávila Saldaña; Ami J Shah; Katja G Weinacht; Avni Joshi; Farid Boulad; Troy C Quigg; Christopher C Dvorak; Debi Grossman; Troy Torgerson; Pamela Graham; Vinod Prasad; Alan Knutsen; Hey Chong; Holly Miller; M Teresa de la Morena; Kenneth DeSantes; Morton J Cowan; Luigi D Notarangelo; Donald B Kohn; Elizabeth Stenger; Sung-Yun Pai; John M Routes; Jennifer M Puck; Neena Kapoor; Michael A Pulsipher; Harry L Malech; Suhag Parikh; Elizabeth M Kang Journal: J Clin Immunol Date: 2019-08-02 Impact factor: 8.317